Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

NCT ID: NCT00481832

Last Updated: 2018-02-14

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-01-31
• Study Completion Date: 2017-03-30

Brief Summary

The purpose of this trial is to develop an alternative treatment for patients with poor risk non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem cell transplant using the patient's own cells. This is followed with non-myeloablative transplant using stem cells from a related or unrelated donor to try and generate an anti-lymphoma response from the new immune system.

Detailed Description

Currently, patients with recurrent or primary refractory non-Hodgkin's lymphoma are treated with second-line chemotherapy (usually 2-3 courses) for the purpose of cytoreduction and to establish sensitivity to chemotherapy. Thereafter, peripheral blood progenitor cells are mobilized with cyclophosphamide and granulocyte colony stimulating factor, apheresed and cryopreserved. The standard high dose regimen consists of augmented carmustine, etoposide and cyclophosphamide. Unfortunately, there are subgroups of patients with poor outcomes using autologous transplantation including those with transformed lymphoma as well as patients who do not attain a minimal disease state due to chemoresistant disease.

These groups of patients have limited disease control and survival with standard chemotherapy regimens, and although they often have excellent cytoreduction with the high-dose chemotherapy regimen, relapse remains the primary cause of treatment failure. The current trial utilizes a similar approach that has been taken with patients with multiple myeloma, who appear to benefit from an allogeneic graft-versus-tumor effect, using a combined autologous and non-myeloablative allogeneic transplant regimen to reduce transplant-related complications. Eligible patients will be treated with high-dose chemotherapy using BCNU, etoposide and cyclophosphamide with autologous hematopoietic cell support as a method of cytoreduction. Approximately 60-120 days after the autologous transplant, patients will receive an allogeneic transplant using a preparative regimen of total lymphoid irradiation and anti-thymocyte globulin in an attempt to develop a graft-versus-lymphoma effect.

Conditions

Lymphoma, Non-Hodgkin

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

T & B Cell Mobilization Auto & Allo HCT

A transplant regimen that conditions the subjects using total lymphoid irradiation (TLI) and anti-thymocyte globulin(ATG) which will reduce acute graft-vs-host disease to negligible rates while maintaining the anti-tumor graft vs lymphoma GvL benefit. Along with TLI/ATG regiment; Solumedrol will be used as pre-medication and anti-emetic for any side effects. For stem cell mobilization, participants will be given either B Cell NLH or T Cell NHL. Before the filgrastim (G-CSF) mobilized PBPC infusion: acetaminophen, diphenhydramine and hydrocortisone will also be given as another set of pre-medications. BCNU, Etoposide, and Cyclophosphamide will be used as a preparative regimen. Cyclosporine and mycophenolate mofetil will be administered as an immunosuppressant after transplantation. Lastly, rituximab will be infused at the end of the transplantation regimen.

Group Type: EXPERIMENTAL

Cyclophosphamide

Intervention Type: DRUG

4 gm /m² IV over 2 hours on day 8

BCNU

Intervention Type: DRUG

The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:

Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)

Etoposide

Intervention Type: DRUG

60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².

Filgrastim

Intervention Type: DRUG

10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis

Antithymocyte globulin

Intervention Type: DRUG

1.5 mg/kg/d, IV from day -11 to -7

Cyclosporine

Intervention Type: DRUG

5mg/kgbid,variable, po or IV

Mycophenolate mofetil

Intervention Type: DRUG

15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.

Rituximab

Intervention Type: DRUG

375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..

Autologous hematopoietic stem cell transplantation (auto-HSCT)

Intervention Type: PROCEDURE

Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents

Allogeneic hematopoietic stem cell transplantation (allo-HSCT)

Intervention Type: PROCEDURE

Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)

Total lymphoid irradiation

Intervention Type: PROCEDURE

TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT

CD34+ Cells

Intervention Type: DRUG

2 x 10e6 CD34+ cells per kg actual body weight on Day 0

Solu-Medrol

Intervention Type: DRUG

1 mg/kg, Day-11 to Day-7

Interventions

Cyclophosphamide

4 gm /m² IV over 2 hours on day 8

Intervention Type: DRUG

BCNU

The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:

Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)

Intervention Type: DRUG

Etoposide

60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².

Intervention Type: DRUG

Filgrastim

10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis

Intervention Type: DRUG

Antithymocyte globulin

1.5 mg/kg/d, IV from day -11 to -7

Intervention Type: DRUG

Cyclosporine

5mg/kgbid,variable, po or IV

Intervention Type: DRUG

Mycophenolate mofetil

15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.

Intervention Type: DRUG

Rituximab

375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..

Intervention Type: DRUG

Autologous hematopoietic stem cell transplantation (auto-HSCT)

Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents

Intervention Type: PROCEDURE

Allogeneic hematopoietic stem cell transplantation (allo-HSCT)

Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)

Intervention Type: PROCEDURE

Total lymphoid irradiation

TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT

Intervention Type: PROCEDURE

CD34+ Cells

2 x 10e6 CD34+ cells per kg actual body weight on Day 0

Intervention Type: DRUG

Solu-Medrol

1 mg/kg, Day-11 to Day-7

Intervention Type: DRUG

Other Intervention Names

Cytoxan; Neosar; BiCNU; Carmustine; Eposin; Etopophos; VP-16; Granulocyte colony-stimulating factor (G-CSF, GCSF); Colony-stimulating factor (CSF) 3; ATG; cyclosporin; cyclosporin A; MMF; CellCep; Rituxan; MabThera; Autologous peripheral blood progenitor cell (PBPC) transplantation; Allogeneic peripheral blood progenitor cell (PBPC) transplantation; TLI; Methylprednisolone

Eligibility Criteria

Inclusion Criteria

• Age 18 to 70 years.
• Histologically proven non-Hodgkin's lymphoma
• Relapse after achieving initial remission or failure to achieve initial remission.
• KPS > 70%
• Matched related or unrelated donor identified and available. Donor must be a complete match or have only a single allele mismatch.
• Recent Bone marrow biopsy and cytogenetic analysis
• Patients must have a pretreatment serum bilirubin < 2 x the institutional ULN, a serum creatinine < 2 x the institutional ULN and measured or estimated creatinine clearance > 50 cc/min by the following formula (all tests must be performed within 28 days prior to mobilization ): Estimated Creatinine Clearance = (140 age) X WT(kg) X 0.85 if female 72 X serum creatinine(mg/dl).
• Patients must have an EKG within 42 days prior to registration that shows no significant abnormalities that are suggestive of active cardiac disease.
• Patients must have an echocardiogram or MUGA scan within 42 days of registration. If the ejection fraction is < 40%, the patient will not be eligible. If the ejection fraction is 40-50%, patients must have an exercise echocardiogram or dobutamine-echo with a normal response to exercise.
• Patients must have a corrected diffusion capacity > 50% prior to the autologous transplant and > 40% prior to the allogeneic transplant.
• Patients with known allergy to etoposide or a history of Grade 3 hemorrhagic cystitis with cyclophosphamide are not eligible.
• Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.

Exclusion Criteria

• Pregnant or breast-feeding women are ineligible due to the known birth defects association with the treatments used in this study.
• Patients known to be human immunodeficiency virus (HIV)-positive are ineligible because the concern for opportunistic infection and hematologic reserve are considered to be significantly greater in this population.
• Patients with prior maligancies diagnosed > 5 years ago without evidence of disease are eligible. Patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligible.
• Patients with uncontrolled infection.
• No prior autologous or allogeneic hematopoietic cell transplantation.

Donor Selection/Evaluation:

• Related or unrelated HLA identical donors who are in good health and have no contra-indication to donation.
• No contra-indication for the donor to collection by apheresis of mononuclear cells mobilized by G-CSF at a dose of 16 µg/kg of body weight.
• Virology testing including CMV, HIV, EBV, HTLV, RPR, Hepatitis A, B and C will be performed within 30 days of donation.
• No prior malignancy is allowed except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the donor has been disease-free for five years

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stanford University

OTHER

Sponsor Role: lead

Responsible Party

Wen-Kai Weng

Associate Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Wen-Kai Weng

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Stanford University School of Medicine

Stanford, California, United States

Countries

United States

Other Identifiers

97623

Identifier Type: OTHER

Identifier Source: secondary_id

BMT185

Identifier Type: OTHER

Identifier Source: secondary_id

IRB-05730

Identifier Type: -

Identifier Source: org_study_id